What is Stifel Canada's Estimate for TSE:GUD Q2 Earnings?

Knight Therapeutics Inc. (TSE:GUD - Free Report) - Equities researchers at Stifel Canada issued their Q2 2025 EPS estimates for Knight Therapeutics in a research note issued to investors on Monday, March 24th. Stifel Canada analyst J. Keywood forecasts that the company will earn $0.04 per share for the quarter. The consensus estimate for Knight Therapeutics' current full-year earnings is $0.10 per share. Stifel Canada also issued estimates for Knight Therapeutics' FY2025 earnings at $0.17 EPS.

Several other analysts also recently issued reports on GUD. Canaccord Genuity Group downgraded Knight Therapeutics from a "strong-buy" rating to a "hold" rating in a research note on Friday, March 21st. Research Capitl upgraded Knight Therapeutics from a "hold" rating to a "strong-buy" rating in a report on Tuesday, March 11th. Finally, Stifel Nicolaus boosted their price objective on shares of Knight Therapeutics from C$6.25 to C$7.45 and gave the stock a "buy" rating in a research note on Tuesday, March 25th. One investment analyst has rated the stock with a hold rating, one has issued a buy rating and two have given a strong buy rating to the stock. According to data from MarketBeat, Knight Therapeutics presently has an average rating of "Buy" and an average price target of C$7.48.

Knight Therapeutics Stock Up 1.5 %

Shares of Knight Therapeutics stock traded up C$0.09 during midday trading on Wednesday, reaching C$6.09. 58,415 shares of the company's stock traded hands, compared to its average volume of 70,839. The company has a market cap of C$616.00 million, a price-to-earnings ratio of -20.33, a price-to-earnings-growth ratio of -1,013.50 and a beta of 0.50. Knight Therapeutics has a 52 week low of C$5.09 and a 52 week high of C$6.45. The company's 50 day simple moving average is C$5.74 and its 200 day simple moving average is C$5.60. The company has a debt-to-equity ratio of 7.52, a quick ratio of 1.79 and a current ratio of 3.36.

Remove Ads

Insider Activity at Knight Therapeutics

In other Knight Therapeutics news, insider Sime Armoyan sold 2,500,000 shares of Knight Therapeutics stock in a transaction on Friday, March 21st. The stock was sold at an average price of C$6.30, for a total transaction of C$15,750,000.00. Insiders sold a total of 3,143,300 shares of company stock worth $19,733,740 in the last ninety days. 45.62% of the stock is currently owned by insiders.

About Knight Therapeutics

Knight Therapeutics Inc develops, manufactures, acquires, in-licenses, out-licenses, markets, and distributes pharmaceutical and consumer health products, and medical devices worldwide. It offers Tafasitamab for relapsed or refractory diffuse large B-cell lymphoma; Pemigatinib for metastatic cholangiocarcinoma; Akynzeo for prevention of chemotherapy-induced acute and delayed nausea and vomiting; Aloxi for prevention of acute nausea and vomiting associated with emetogenic cancer chemotherapy; Fostamatinib for chronic immune thrombocytopenia; Nerlynx for extended adjuvant breast cancer and metastatic breast cancer; Trelstar for advanced prostate cancer; Vidaza for myelodysplastic syndrome; Abraxane for metastatic pancreatic cancer; Halaven for metastatic breast cancer and soft tissue sarcoma; and Lenvima for advanced renal cell cancer and for differentiated thyroid cancer and unresectable hepatocellular carcinoma.